Ayhan Algul
Research Subjects
Research Interests
Ayhan Algul has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Mesut Cetin
Psychiatry &Clinical Psychopharmacology and Psychiatry and Behavioral Sciences, Istanbul, Turkey
18 shared publications Cengiz Basoglu
14 shared publicationsServet Ebrinc
14 shared publications- İbRahim Gundogmus
Department of Psychiatry, İstanbul Nişantaşı University, School of Medicine, İstanbul, Turkey
12 shared publications Alpay Ates
7 shared publicationsMehmet Alpay Ates
6 shared publications
Latest Publications
- Open Access
- 25 September 2021
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 18 (9) , 841-849
The Relationship of Smartphone Addiction and Alexithymia
Objective This study aims to evaluate whether smartphone addiction (SA) is associated with social media use and alexithymia levels in university students.Methods A group of 935 students aged between 18 and 45 years (509 females and 426 males) was recruited from different universities in Istanbul. SAs, alexithymia and social media use were assessed using the Smartphone Addiction Scale Short Version (SAS-SV), Toronto Alexithymia Scale-20 (TAS-20), and ad-hoc questions regarding social media use.Results The mean age of participants was 21.89±3.27 years and 509 of participants were female (54.4%). 455 (48.6%) participants were placed in the “SA” and 198 (21.2%) in the “alexithymia” categories. The study found a high level of positive correlation (p<0.001) between both subscale and total TAS-20 scores and SAS-SV scores. Gender (OR=1.496, 95% CI 1.117–2.002, p=0.007) and number of social media by participants (OR=1.221, 95% CI 1.134–1.315, p<0.001) and TAS (OR=1.074, 95% CI 1.059–1.090, p<0.001) were found to be an independent predictors for SA.Conclusion The study revealed a positive correlation between alexithymia and smartphone use severity, and alexithymia was a significant predictor of SA. Future studies focusing on the causal aspect of this relationship will be useful in planning strategies for treatment.
- 25 September 2021
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 18 (9) , 841-849
Open AccessThe Relationship of Smartphone Addiction and Alexithymia
Objective This study aims to evaluate whether smartphone addiction (SA) is associated with social media use and alexithymia levels in university students.Methods A group of 935 students aged between 18 and 45 years (509 females and 426 males) was recruited from different universities in Istanbul. SAs, alexithymia and social media use were assessed using the Smartphone Addiction Scale Short Version (SAS-SV), Toronto Alexithymia Scale-20 (TAS-20), and ad-hoc questions regarding social media use.Results The mean age of participants was 21.89±3.27 years and 509 of participants were female (54.4%). 455 (48.6%) participants were placed in the “SA” and 198 (21.2%) in the “alexithymia” categories. The study found a high level of positive correlation (p<0.001) between both subscale and total TAS-20 scores and SAS-SV scores. Gender (OR=1.496, 95% CI 1.117–2.002, p=0.007) and number of social media by participants (OR=1.221, 95% CI 1.134–1.315, p<0.001) and TAS (OR=1.074, 95% CI 1.059–1.090, p<0.001) were found to be an independent predictors for SA.Conclusion The study revealed a positive correlation between alexithymia and smartphone use severity, and alexithymia was a significant predictor of SA. Future studies focusing on the causal aspect of this relationship will be useful in planning strategies for treatment.
- Open Access
- 1 December 2018
- Published by Kare Publishing in Dusunen Adam: Journal of Psychiatry and Neurological Sciences
- Vol. 31 (4) , 409-412
Venlafaxine-Induced Hematuria and Prostatism: a Case Report
Hematuria and prostatism are important medical conditions affecting the quality of life. They are most often seen causally related to prostate hyperplasia but may also occur as a side effect of certain medications. Although the urogenital side effects of antidepressants are common in the literature, reports that indicate antidepressant induced hematuria are rare. Venlafaxine, an antidepressant that inhibits serotonin-noradrenaline reuptake, is used in clinical practice in a number of psychiatric disorders, especially in major depressive disorder. Although it is a safe and effective antidepressant, it can cause side effects. We present a 55-year-old man with hematuria and symptoms of prostatism starting after the use of venlafaxine that resolved after the withdrawal of venlafaxine. In the literature, symptoms of prostatism have been reported related to antidepressants that are effective through the noradrenaline mechanism, such as venlafaxine, duloxetine, milnacipran, and reboxetine, but there are no reports on hematuria. As far as we know, this is the first report to present a case of venlafaxine-induced hematuria.
- 1 December 2018
- Published by Kare Publishing in Dusunen Adam: Journal of Psychiatry and Neurological Sciences
- Vol. 31 (4) , 409-412
Open AccessVenlafaxine-Induced Hematuria and Prostatism: a Case Report
Hematuria and prostatism are important medical conditions affecting the quality of life. They are most often seen causally related to prostate hyperplasia but may also occur as a side effect of certain medications. Although the urogenital side effects of antidepressants are common in the literature, reports that indicate antidepressant induced hematuria are rare. Venlafaxine, an antidepressant that inhibits serotonin-noradrenaline reuptake, is used in clinical practice in a number of psychiatric disorders, especially in major depressive disorder. Although it is a safe and effective antidepressant, it can cause side effects. We present a 55-year-old man with hematuria and symptoms of prostatism starting after the use of venlafaxine that resolved after the withdrawal of venlafaxine. In the literature, symptoms of prostatism have been reported related to antidepressants that are effective through the noradrenaline mechanism, such as venlafaxine, duloxetine, milnacipran, and reboxetine, but there are no reports on hematuria. As far as we know, this is the first report to present a case of venlafaxine-induced hematuria.
- Open Access
- 27 September 2018
- Published by Kare Publishing in Dusunen Adam: Journal of Psychiatry and Neurological Sciences
- Vol. 31 (3) , 304-307
Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report
Therapeutic single dosage mirtazapine-induced symptomatic bradycardia: a case report
- 27 September 2018
- Published by Kare Publishing in Dusunen Adam: Journal of Psychiatry and Neurological Sciences
- Vol. 31 (3) , 304-307
Open AccessTherapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report
Therapeutic single dosage mirtazapine-induced symptomatic bradycardia: a case report
- Open Access
- 3 May 2018
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 29 (4) , 520-526
PDW and RDW are new parameters for bipolar episodes and unipolar depression
INTRODUCTION: Bipolar disorder (BD) and unipolar depression (UD) are complex and multifactorial mental disorders characterized by mood swings, disability, and impaired quality of life. In the present study, we researched the roles of inflammatory cells and their value as inflammation markers in BD and UD. OBJECTIVE: Sixty-nine manic, 60 euthymic, and 70 UD patients and 60 sex-matched healthy volunteers (control group) were retrospectively analysed. Platelet (PLT), platelet distribution width (PDW), and red cell distribution width (RDW) levels were measured in four groups. The aim of this study was to evaluate PLT, PDW, and RDW levels patient with UD and two different phases of BD: euthymic and manic. RESULTS: In our study, 199 patients and 60 controls were included. There were no differences between the patients and the healthy control group participants in terms of age and sex. The bipolar episodes and the UD patient group were statistically significantly different from the healthy controls in terms of PLT, PDW, and RDW. CONCLUSION: Our study is the first in the literature to compare blood PLT, PDW, and RDW levels in bipolar episodes, UD patients, and healthy control groups. We believe that the levels of PLT, PDW, and RDW can be used as novel markers of bipolar episodes and UD. More detailed and larger prospective clinical studies are required to confirm these findings.
- 3 May 2018
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 29 (4) , 520-526
Open AccessPDW and RDW are new parameters for bipolar episodes and unipolar depression
INTRODUCTION: Bipolar disorder (BD) and unipolar depression (UD) are complex and multifactorial mental disorders characterized by mood swings, disability, and impaired quality of life. In the present study, we researched the roles of inflammatory cells and their value as inflammation markers in BD and UD. OBJECTIVE: Sixty-nine manic, 60 euthymic, and 70 UD patients and 60 sex-matched healthy volunteers (control group) were retrospectively analysed. Platelet (PLT), platelet distribution width (PDW), and red cell distribution width (RDW) levels were measured in four groups. The aim of this study was to evaluate PLT, PDW, and RDW levels patient with UD and two different phases of BD: euthymic and manic. RESULTS: In our study, 199 patients and 60 controls were included. There were no differences between the patients and the healthy control group participants in terms of age and sex. The bipolar episodes and the UD patient group were statistically significantly different from the healthy controls in terms of PLT, PDW, and RDW. CONCLUSION: Our study is the first in the literature to compare blood PLT, PDW, and RDW levels in bipolar episodes, UD patients, and healthy control groups. We believe that the levels of PLT, PDW, and RDW can be used as novel markers of bipolar episodes and UD. More detailed and larger prospective clinical studies are required to confirm these findings.
- Open Access
- 9 April 2018
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (4) , 461-463
First-episode psychosis induced by pregabalin withdrawal: a case report
Pregabalin is a novel isomer of gamma-aminobutyric acid that functions as a major inhibitory neurotransmitter in the brain. It is used daily in medical practice for treating neuropathic pain, fibromyalgia, generalized anxiety disorder, and partial seizures. Due to its anti-glutamatergic effects, it poses a potential addiction risk. For example, an abrupt discontinuation of this substance may cause patients to exhibit physical withdrawal symptoms, such as insomnia, nausea, headache, and diarrhoea. However, there is no information in the literature that addresses whether the rapid discontinuation of pregabalin can cause psychosis to occur. Here we presented a 20-year-old patient with his first episode of psychosis that was likely attributable to his withdrawal from a high dosage pregabalin. He lacked physical signs of withdrawal; however, a psychiatric examination was conducted. It was determined that the patient was experiencing paranoid ideation, auditory hallucinations, and mutism. Furthermore, he had engaged in self-mutilative actions and had attempted suicide. Due to the short time frame between the rapid discontinuation of a relatively large dose of pregabalin and the onset of the patient’s first episode of psychosis, it is likely that the psychotic episode was triggered by the cessation of the medication. This is the first known case of psychosis that was caused by the rapid withdrawal of pregabalin to be discussed in the literature. The results of this clinical case may guide clinicians to recognize the symptoms of acute pregabalin withdrawal.
- 9 April 2018
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (4) , 461-463
Open AccessFirst-episode psychosis induced by pregabalin withdrawal: a case report
Pregabalin is a novel isomer of gamma-aminobutyric acid that functions as a major inhibitory neurotransmitter in the brain. It is used daily in medical practice for treating neuropathic pain, fibromyalgia, generalized anxiety disorder, and partial seizures. Due to its anti-glutamatergic effects, it poses a potential addiction risk. For example, an abrupt discontinuation of this substance may cause patients to exhibit physical withdrawal symptoms, such as insomnia, nausea, headache, and diarrhoea. However, there is no information in the literature that addresses whether the rapid discontinuation of pregabalin can cause psychosis to occur. Here we presented a 20-year-old patient with his first episode of psychosis that was likely attributable to his withdrawal from a high dosage pregabalin. He lacked physical signs of withdrawal; however, a psychiatric examination was conducted. It was determined that the patient was experiencing paranoid ideation, auditory hallucinations, and mutism. Furthermore, he had engaged in self-mutilative actions and had attempted suicide. Due to the short time frame between the rapid discontinuation of a relatively large dose of pregabalin and the onset of the patient’s first episode of psychosis, it is likely that the psychotic episode was triggered by the cessation of the medication. This is the first known case of psychosis that was caused by the rapid withdrawal of pregabalin to be discussed in the literature. The results of this clinical case may guide clinicians to recognize the symptoms of acute pregabalin withdrawal.
- Open Access
- 11 December 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (3) , 339-342
Treatment of ADHD in a patient with Brugada syndrome: a case report and a brief review
The Brugada syndrome is one of the common causes of sudden cardiac arrest in healthy-appearing adults. The use of drugs in the treatment of this disease may give variable and unwanted results. Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioural disorder which has begun to be noticed in adults as much as children. In our case, we present a 39-year-old male patient with an ADHD who was diagnosed with the Brugada syndrome during a routine examination and we discuss the treatment of this case. The association of ADHD and Brugada syndrome has not been previously reported in any clinical study. As far as we know, the present case is the first article in the literature to discuss the follow-up and treatment of ADHD in a patient with the Brugada syndrome. We observed all medical and non-medical treatment methods for ADHD treatment and discussed these methods such as psychostimulants, atomoxetine, bupropion, and psychotherapy.
- 11 December 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (3) , 339-342
Open AccessTreatment of ADHD in a patient with Brugada syndrome: a case report and a brief review
The Brugada syndrome is one of the common causes of sudden cardiac arrest in healthy-appearing adults. The use of drugs in the treatment of this disease may give variable and unwanted results. Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioural disorder which has begun to be noticed in adults as much as children. In our case, we present a 39-year-old male patient with an ADHD who was diagnosed with the Brugada syndrome during a routine examination and we discuss the treatment of this case. The association of ADHD and Brugada syndrome has not been previously reported in any clinical study. As far as we know, the present case is the first article in the literature to discuss the follow-up and treatment of ADHD in a patient with the Brugada syndrome. We observed all medical and non-medical treatment methods for ADHD treatment and discussed these methods such as psychostimulants, atomoxetine, bupropion, and psychotherapy.
- Open Access
- 14 June 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (1) , 97-99
Alopecia associated with agomelatine use: a case report
Drug-induced alopecia, characterized by non-scarring hair loss of scalp and body, is a rare side effect of psychotropic drugs. It has previously been reported with the different antidepressant medications, but has not been described with agomelatine. Agomelatine is an antidepressant with a novel mechanism of action and fewer side effects. Here, we report a 31-year-old male patient with diffuse hair loss induced by agomelatine use and improved by discontinuation the drug. Because antidepressant-induced hair loss is relatively rare, many clinicians may not pay attention for this side effect. As far as we know, this is the first published case report of alopecia associated with agomelatine.
- 14 June 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 28 (1) , 97-99
Open AccessAlopecia associated with agomelatine use: a case report
Drug-induced alopecia, characterized by non-scarring hair loss of scalp and body, is a rare side effect of psychotropic drugs. It has previously been reported with the different antidepressant medications, but has not been described with agomelatine. Agomelatine is an antidepressant with a novel mechanism of action and fewer side effects. Here, we report a 31-year-old male patient with diffuse hair loss induced by agomelatine use and improved by discontinuation the drug. Because antidepressant-induced hair loss is relatively rare, many clinicians may not pay attention for this side effect. As far as we know, this is the first published case report of alopecia associated with agomelatine.
- Open Access
- 21 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (2) , 197-198
Venlafaxine-induced prostatism: a case report
Venlafaxine, which is often used for a number of psychiatric-related conditions such as the treatment of major depression, generalized anxiety disorder, social anxiety disorder and panic disorder, is generally a drug that is well tolerated and safe. The side effects of drugs can cause the treatment to prematurely terminate. Clinicians should prefer appropriate and low side-effects drugs to prevent this. This situation is also especially important for psychiatric patients. Prostatism, which impairs quality of life, is an important medical condition, with clinical and social implications. In the previous studies, prostatism was declared as a side effect of some antidepressant such as milnacipran, duloxetine and reboxetine. In our case, we discussed that venlafaxine-related prostatism developed in a male patient. As far as we know this is the first report of venlafaxine-induced prostatism.
- 21 March 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (2) , 197-198
Open AccessVenlafaxine-induced prostatism: a case report
Venlafaxine, which is often used for a number of psychiatric-related conditions such as the treatment of major depression, generalized anxiety disorder, social anxiety disorder and panic disorder, is generally a drug that is well tolerated and safe. The side effects of drugs can cause the treatment to prematurely terminate. Clinicians should prefer appropriate and low side-effects drugs to prevent this. This situation is also especially important for psychiatric patients. Prostatism, which impairs quality of life, is an important medical condition, with clinical and social implications. In the previous studies, prostatism was declared as a side effect of some antidepressant such as milnacipran, duloxetine and reboxetine. In our case, we discussed that venlafaxine-related prostatism developed in a male patient. As far as we know this is the first report of venlafaxine-induced prostatism.
- Open Access
- 2 January 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (1) , 96-98
Mianserin induced periorbital edema: a case report
Objectives: The rare side effects as periorbital edema are worth to discuss most of the times. Periorbital edema is a rare and serious allergic condition. The etiology of this situation might be seen in different status that they are commonly independent of each other’s as well as their various speculated formation mechanisms. The drug induced side effects might be seen in the etiologic factors basket of periorbital edema. Methods: Observational case report. Results: The authors describe a 30-year-old woman with generalized anxiety disorder who developed periorbital edema while undergoing of treatment with mianserin. Conclusions: Interestingly, we observed a relationship with periorbital edema and a safe, effective, well-tolerated atypical antidepressant-mianserin. This is the first-demonstrated case in literature periorbital edema due to mianserin. The case is enormous importance for contributing the side effect set of periorbital edema. Thus, it will be useful contribution for the daily practice of physicians and the other professions.
- 2 January 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (1) , 96-98
Open AccessMianserin induced periorbital edema: a case report
Objectives: The rare side effects as periorbital edema are worth to discuss most of the times. Periorbital edema is a rare and serious allergic condition. The etiology of this situation might be seen in different status that they are commonly independent of each other’s as well as their various speculated formation mechanisms. The drug induced side effects might be seen in the etiologic factors basket of periorbital edema. Methods: Observational case report. Results: The authors describe a 30-year-old woman with generalized anxiety disorder who developed periorbital edema while undergoing of treatment with mianserin. Conclusions: Interestingly, we observed a relationship with periorbital edema and a safe, effective, well-tolerated atypical antidepressant-mianserin. This is the first-demonstrated case in literature periorbital edema due to mianserin. The case is enormous importance for contributing the side effect set of periorbital edema. Thus, it will be useful contribution for the daily practice of physicians and the other professions.
- Open Access
- 2 January 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (1) , 14-18
Evaluation of repetitive transcranial magnetic stimulation for treatment-resistant major depression and the impact of anxiety symptoms on outcome
- 2 January 2017
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (1) , 14-18
Open AccessEvaluation of repetitive transcranial magnetic stimulation for treatment-resistant major depression and the impact of anxiety symptoms on outcome